{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:51:58Z","timestamp":1790693518452,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"48","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,11,30]]},"DOI":"10.1038\/onc.2017.279","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T15:02:36Z","timestamp":1502722956000},"page":"6680-6690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance"],"prefix":"10.1038","volume":"36","author":[{"given":"R R","family":"Somasagara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D W","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Madeira da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Scalici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kothayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"Westwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R P","family":"Rocconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Palle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"BFonc2017279_CR1","first-page":"288","volume":"27","author":"OW Foley","year":"2013","unstructured":"Foley OW, Rauh-Hain JA, del Carmen MG . Recurrent epithelial ovarian cancer: an update on treatment. Oncology 2013; 27: 288\u2013294, 298.","journal-title":"Oncology"},{"key":"BFonc2017279_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M . \u2018Platinum resistant\u2019 ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 2014; 133: 624\u2013631.","journal-title":"Gynecol Oncol"},{"key":"BFonc2017279_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.2009.27.2369","volume":"29","author":"LE Kandalaft","year":"2011","unstructured":"Kandalaft LE, Powell DJ, Singh N, Coukos G . Immunotherapy for ovarian cancer: what\u2019s next? J Clin Oncol 2011; 29: 925\u2013933.","journal-title":"J Clin Oncol"},{"key":"BFonc2017279_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK-H . Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2: 3.","journal-title":"Clin Transl Med"},{"key":"BFonc2017279_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.drudis.2015.06.013","volume":"20","author":"IN Khan","year":"2015","unstructured":"Khan IN, Al-Karim S, Bora RS, Chaudhary AG, Saini KS . Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discov Today 2015; 20: 1205\u20131216.","journal-title":"Drug Discov Today"},{"key":"BFonc2017279_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-05-3153","volume":"66","author":"MS Wicha","year":"2006","unstructured":"Wicha MS, Liu S, Dontu G . Cancer stem cells: an old idea\u2014a paradigm shift. Cancer Res 2006; 66: 1883\u20131890.","journal-title":"Cancer Res"},{"key":"BFonc2017279_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/bies.950160408","volume":"16","author":"C Lawrence","year":"1994","unstructured":"Lawrence C . The RAD6 DNA repair pathway in Saccharomyces cerevisiae: what does it do, and how does it do it? BioEssays 1994; 16: 253\u2013258.","journal-title":"BioEssays"},{"key":"BFonc2017279_CR8","doi-asserted-by":"publisher","first-page":"8865","DOI":"10.1073\/pnas.88.20.8865","volume":"88","author":"MH Koken","year":"1991","unstructured":"Koken MH, Reynolds P, Jaspers-Dekker I, Prakash L, Prakash S, Bootsma D et al. Structural and functional conservation of two human homologs of the yeast DNA repair gene RAD6. Proc Natl Acad Sci USA 1991; 88: 8865\u20138869.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017279_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1101\/gad.8.7.811","volume":"8","author":"V Bailly","year":"1994","unstructured":"Bailly V, Lamb J, Sung P, Prakash S, Prakash L . Specific complex formation between yeast RAD6 and RAD18 proteins: a potential mechanism for targeting RAD6 ubiquitin-conjugating activity to DNA damage sites. Genes Dev 1994; 8: 811\u2013820.","journal-title":"Genes Dev"},{"key":"BFonc2017279_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1126\/science.287.5452.501","volume":"287","author":"K Robzyk","year":"2000","unstructured":"Robzyk K, Recht J, Osley MA . Rad6-dependent ubiquitination of histone H2B in yeast. Science 2000; 287: 501\u2013504.","journal-title":"Science"},{"key":"BFonc2017279_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1101\/gad.1149604","volume":"18","author":"C-F Kao","year":"2004","unstructured":"Kao C-F, Hillyer C, Tsukuda T, Henry K, Berger S, Osley MA . Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B. Genes Dev 2004; 18: 184\u2013195.","journal-title":"Genes Dev"},{"key":"BFonc2017279_CR12","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/sj.onc.1207449","volume":"23","author":"A Lyakhovich","year":"2004","unstructured":"Lyakhovich A, Shekhar MPV . RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response. Oncogene 2004; 23: 3097\u20133106.","journal-title":"Oncogene"},{"key":"BFonc2017279_CR13","first-page":"2115","volume":"62","author":"MPV Shekhar","year":"2002","unstructured":"Shekhar MPV, Lyakhovich A, Visscher DW, Heng H, Kondrat N . Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Res 2002; 62: 2115\u20132124.","journal-title":"Cancer Res"},{"key":"BFonc2017279_CR14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1158\/0008-5472.CAN-07-2111","volume":"68","author":"MPV Shekhar","year":"2008","unstructured":"Shekhar MPV, Gerard B, Pauley RJ, Williams BO, Tait L . Rad6B is a positive regulator of beta-catenin stabilization. Cancer Res 2008; 68: 1741\u20131750.","journal-title":"Cancer Res"},{"key":"BFonc2017279_CR15","doi-asserted-by":"publisher","first-page":"439205","DOI":"10.1155\/2014\/439205","volume":"2014","author":"K Rosner","year":"2014","unstructured":"Rosner K, Mehregan DR, Kirou E, Abrams J, Kim S, Campbell M et al. Melanoma development and progression are associated with Rad6 upregulation and \u03b2 -catenin relocation to the cell membrane. J Skin Cancer 2014; 2014: 439205.","journal-title":"J Skin Cancer"},{"key":"BFonc2017279_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbrc.2015.11.134","volume":"469","author":"RR Somasagara","year":"2016","unstructured":"Somasagara RR, Tripathi K, Spencer SM, Clark DW, Barnett R, Bachaboina L et al. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer. Biochem Biophys Res Commun 2016; 469: 449\u2013455.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2017279_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","volume":"5","author":"D Chirnomas","year":"2006","unstructured":"Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman A-R et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway. Mol Cancer Ther 2006; 5: 952\u2013961.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2017279_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3816\/CLC.2005.n.005","volume":"6","author":"M Ferrer","year":"2005","unstructured":"Ferrer M, Span SW, Vischioni B, Oudejans JJ, van Diest PJ, de Winter JP et al. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. Clin Lung Cancer 2005; 6: 250\u2013254.","journal-title":"Clin Lung Cancer"},{"key":"BFonc2017279_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1083\/jcb.201005101","volume":"191","author":"L Geng","year":"2010","unstructured":"Geng L, Huntoon CJ, Karnitz LM . RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. J Cell Biol 2010; 191: 249\u2013257.","journal-title":"J Cell Biol"},{"key":"BFonc2017279_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4161\/cc.3.8.1074","volume":"3","author":"PL Kannouche","year":"2004","unstructured":"Kannouche PL, Lehmann AR . Ubiquitination of PCNA and the polymerase switch in human cells. Cell Cycle 2004; 3: 1011\u20131013.","journal-title":"Cell Cycle"},{"key":"BFonc2017279_CR21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1101\/gad.1103403","volume":"17","author":"S Houghtaling","year":"2003","unstructured":"Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003; 17: 2021\u20132035.","journal-title":"Genes Dev"},{"key":"BFonc2017279_CR22","doi-asserted-by":"publisher","first-page":"34655","DOI":"10.1074\/jbc.C200433200","volume":"277","author":"HH Ng","year":"2002","unstructured":"Ng HH, Xu R-M, Zhang Y, Struhl K . Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem 2002; 277: 34655\u201334657.","journal-title":"J Biol Chem"},{"key":"BFonc2017279_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2009.02.027","volume":"137","author":"J Kim","year":"2009","unstructured":"Kim J, Guermah M, McGinty RK, Lee J-S, Tang Z, Milne TA et al. RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell 2009; 137: 459\u2013471.","journal-title":"Cell"},{"key":"BFonc2017279_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2006.04.029","volume":"125","author":"R Pavri","year":"2006","unstructured":"Pavri R, Zhu B, Li G, Trojer P, Mandal S, Shilatifard A et al. Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 2006; 125: 703\u2013717.","journal-title":"Cell"},{"key":"BFonc2017279_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1101\/gad.211037.112","volume":"27","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Jones A, Joo H-Y, Zhou D, Cao Y, Chen S et al. USP49 deubiquitinates histone H2B and regulates cotranscriptional pre-mRNA splicing. Genes Dev 2013; 27: 1581\u20131595.","journal-title":"Genes Dev"},{"key":"BFonc2017279_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2013.03.012","volume":"49","author":"LM Soares","year":"2013","unstructured":"Soares LM, Buratowski S . Histone Crosstalk: H2Bub and H3K4 Methylation. Mol Cell 2013; 49: 1019\u20131020.","journal-title":"Mol Cell"},{"key":"BFonc2017279_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4161\/epi.5.6.12314","volume":"5","author":"MB Chandrasekharan","year":"2010","unstructured":"Chandrasekharan MB, Huang F, Sun Z-W . Histone H2B ubiquitination and beyond: Regulation of nucleosome stability, chromatin dynamics and the trans-histone H3 methylation. Epigenetics 2010; 5: 460\u2013468.","journal-title":"Epigenetics"},{"key":"BFonc2017279_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.2057811","volume":"25","author":"AT Nguyen","year":"2011","unstructured":"Nguyen AT, Zhang Y . The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011; 25: 1345\u20131358.","journal-title":"Genes Dev"},{"key":"BFonc2017279_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.bbamcr.2012.05.032","volume":"1823","author":"B Gerard","year":"2012","unstructured":"Gerard B, Sanders MA, Visscher DW, Tait L, Shekhar MPV . Lysine 394 is a novel Rad6B-induced ubiquitination site on beta-catenin. Biochim Biophys Acta 2012; 1823: 1686\u20131696.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2017279_CR30","doi-asserted-by":"publisher","first-page":"7368","DOI":"10.1128\/MCB.00744-08","volume":"28","author":"GS Yochum","year":"2008","unstructured":"Yochum GS, Cleland R, Goodman RH . A genome-wide screen for \u03b2-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol 2008; 28: 7368\u20137379.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017279_CR31","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/onc.2014.178","volume":"34","author":"S Condello","year":"2015","unstructured":"Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD et al. \u03b2-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene 2015; 34: 2297\u20132308.","journal-title":"Oncogene"},{"key":"BFonc2017279_CR32","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1128\/MCB.23.7.2463-2475.2003","volume":"23","author":"A Lyakhovich","year":"2003","unstructured":"Lyakhovich A, Shekhar MPV . Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. Mol Cell Biol 2003; 23: 2463\u20132475.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017279_CR33","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.bmcl.2016.02.085","volume":"26","author":"H Kothayer","year":"2016","unstructured":"Kothayer H, Spencer SM, Tripathi K, Westwell AD, Palle K . Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. Bioorg Med Chem Lett 2016; 26: 2030\u20132034.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFonc2017279_CR34","doi-asserted-by":"publisher","first-page":"6886","DOI":"10.1016\/j.bmcl.2013.09.087","volume":"23","author":"H Kothayer","year":"2013","unstructured":"Kothayer H, Elshanawani AA, Abu Kull ME, El-Sabbagh OI, Shekhar MPV, Brancale A et al. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorg Med Chem Lett 2013; 23: 6886\u20136889.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFonc2017279_CR35","doi-asserted-by":"publisher","first-page":"e107142","DOI":"10.1371\/journal.pone.0107142","volume":"9","author":"E Meng","year":"2014","unstructured":"Meng E, Mitra A, Tripathi K, Finan MA, Scalici J, McClellan S et al. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PloS One 2014; 9: e107142.","journal-title":"PloS One"},{"key":"BFonc2017279_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555\u2013567.","journal-title":"Cell Stem Cell"},{"key":"BFonc2017279_CR37","doi-asserted-by":"publisher","first-page":"518","DOI":"10.21037\/atm.2016.11.82","volume":"4","author":"DW Clark","year":"2016","unstructured":"Clark DW, Palle K . Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med 2016; 4: 518.","journal-title":"Ann Transl Med"},{"key":"BFonc2017279_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.nano.2015.10.010","volume":"12","author":"B Haynes","year":"2016","unstructured":"Haynes B, Zhang Y, Liu F, Li J, Petit S, Kothayer H et al. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomed Nanotechnol Biol Med 2016; 12: 745\u2013757.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"BFonc2017279_CR39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tranon.2014.04.009","volume":"7","author":"K Rosner","year":"2014","unstructured":"Rosner K, Adsule S, Haynes B, Kirou E, Kato I, Mehregan DR et al. Rad6 is a potential early marker of melanoma Development. Transl Oncol 2014; 7: 384\u2013392.","journal-title":"Transl Oncol"},{"key":"BFonc2017279_CR40","first-page":"627","volume":"17","author":"B Djordjevic","year":"2012","unstructured":"Djordjevic B, Stojanovic S, Conic I, Jankovic-Velickovic L, Vukomanovic P, Zivadinovic R et al. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. J BUON 2012; 17: 627\u2013636.","journal-title":"J BUON"},{"key":"BFonc2017279_CR41","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1038\/onc.2014.371","volume":"34","author":"S Kobayashi","year":"2015","unstructured":"Kobayashi S, Kasaishi Y, Nakada S, Takagi T, Era S, Motegi A et al. Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining. Oncogene 2015; 34: 4403\u20134411.","journal-title":"Oncogene"},{"key":"BFonc2017279_CR42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1097-2765(04)00259-X","volume":"14","author":"PL Kannouche","year":"2004","unstructured":"Kannouche PL, Wing J, Lehmann AR . Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. Mol Cell 2004; 14: 491\u2013500.","journal-title":"Mol Cell"},{"key":"BFonc2017279_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev.biochem.74.082803.133250","volume":"74","author":"S Prakash","year":"2005","unstructured":"Prakash S, Johnson RE, Prakash L . Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu Rev Biochem 2005; 74: 317\u2013353.","journal-title":"Annu Rev Biochem"},{"key":"BFonc2017279_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/embor.2012.78","volume":"13","author":"S Braun","year":"2012","unstructured":"Braun S, Madhani HD . Shaping the landscape: mechanistic consequences of ubiquitin modification of chromatin. EMBO Rep 2012; 13: 619\u2013630.","journal-title":"EMBO Rep"},{"key":"BFonc2017279_CR45","doi-asserted-by":"publisher","first-page":"E2205","DOI":"10.1073\/pnas.1612633114","volume":"114","author":"S-H Hung","year":"2017","unstructured":"Hung S-H, Wong RP, Ulrich HD, Kao C-F . Monoubiquitylation of histone H2B contributes to the bypass of DNA damage during and after DNA replication. Proc Natl Acad Sci USA 2017; 114: E2205\u2013E2214.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017279_CR46","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.4161\/cc.26640","volume":"12","author":"CM Helchowski","year":"2013","unstructured":"Helchowski CM, Skow LF, Roberts KH, Chute CL, Canman CE . A small ubiquitin binding domain inhibits ubiquitin-dependent protein recruitment to DNA repair foci. Cell Cycle 2013; 12: 3749\u20133758.","journal-title":"Cell Cycle"},{"key":"BFonc2017279_CR47","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1128\/MCB.26.9.3527-3540.2006","volume":"26","author":"X Bi","year":"2006","unstructured":"Bi X, Barkley LR, Slater DM, Tateishi S, Yamaizumi M, Ohmori H et al. Rad18 regulates DNA polymerase kappa and is required for recovery from S-phase checkpoint-mediated arrest. Mol Cell Biol 2006; 26: 3527\u20133540.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017279_CR48","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4161\/cc.10.10.15617","volume":"10","author":"K Palle","year":"2011","unstructured":"Palle K, Vaziri C . Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition. Cell Cycle 2011; 10: 1625\u20131638.","journal-title":"Cell Cycle"},{"key":"BFonc2017279_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/1535-7163.MCT-12-0793","volume":"12","author":"MA Sanders","year":"2013","unstructured":"Sanders MA, Brahemi G, Nangia-Makker P, Balan V, Morelli M, Kothayer H et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther 2013; 12: 373\u2013383.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2017279_CR50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1097-2765(02)00802-X","volume":"11","author":"A Wood","year":"2003","unstructured":"Wood A, Krogan NJ, Dover J, Schneider J, Heidt J, Boateng MA et al. Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol Cell 2003; 11: 267\u2013274.","journal-title":"Mol Cell"},{"key":"BFonc2017279_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1097-2765(02)00826-2","volume":"11","author":"WW Hwang","year":"2003","unstructured":"Hwang WW, Venkatasubrahmanyam S, Ianculescu AG, Tong A, Boone C, Madhani HD . A conserved RING finger protein required for histone H2B monoubiquitination and cell size control. Mol Cell 2003; 11: 261\u2013266.","journal-title":"Mol Cell"},{"key":"BFonc2017279_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature00883","volume":"418","author":"Z-W Sun","year":"2002","unstructured":"Sun Z-W, Allis CD . Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 2002; 418: 104\u2013108.","journal-title":"Nature"},{"key":"BFonc2017279_CR53","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.cell.2007.09.046","volume":"131","author":"J-S Lee","year":"2007","unstructured":"Lee J-S, Shukla A, Schneider J, Swanson SK, Washburn MP, Florens L et al. Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell 2007; 131: 1084\u20131096.","journal-title":"Cell"},{"key":"BFonc2017279_CR54","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/cr.2012.114","volume":"22","author":"S Chen","year":"2012","unstructured":"Chen S, Li J, Wang D-L, Sun F-L . Histone H2B lysine 120 monoubiquitination is required for embryonic stem cell differentiation. Cell Res 2012; 22: 1402\u20131405.","journal-title":"Cell Res"},{"key":"BFonc2017279_CR55","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.bbagen.2012.08.010","volume":"1830","author":"SJ K\u00fchl","year":"2013","unstructured":"K\u00fchl SJ, K\u00fchl M . On the role of Wnt\/\u03b2-catenin signaling in stem cells. Biochim Biophys Acta 2013; 1830: 2297\u20132306.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2017279_CR56","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s12015-011-9275-1","volume":"7","author":"T Miki","year":"2011","unstructured":"Miki T, Yasuda S, Kahn M . Wnt\/\u03b2-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 2011; 7: 836\u2013846.","journal-title":"Stem Cell Rev"},{"key":"BFonc2017279_CR57","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12015-014-9515-2","volume":"10","author":"A Ring","year":"2014","unstructured":"Ring A, Kim Y-M, Kahn M . Wnt\/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev 2014; 10: 512\u2013525.","journal-title":"Stem Cell Rev"},{"key":"BFonc2017279_CR58","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0168-9525(02)02707-5","volume":"18","author":"KM Cadigan","year":"2002","unstructured":"Cadigan KM . Wnt signaling\u201420 years and counting. Trends Genet 2002; 18: 340\u2013342.","journal-title":"Trends Genet"},{"key":"BFonc2017279_CR59","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1158\/1541-7786.MCR-06-0136","volume":"4","author":"MPV Shekhar","year":"2006","unstructured":"Shekhar MPV, Tait L, Gerard B . Essential role of T-cell factor\/beta-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells. Mol Cancer Res 2006; 4: 729\u2013745.","journal-title":"Mol Cancer Res"},{"key":"BFonc2017279_CR60","first-page":"312","volume":"4","author":"AMA de la Rocha","year":"2014","unstructured":"de la Rocha AMA, Sampron N, Alonso MM, Matheu A . Role of SOX family of transcription factors in central nervous system tumors. Am J Cancer Res 2014; 4: 312\u2013324.","journal-title":"Am J Cancer Res"},{"key":"BFonc2017279_CR61","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/0008-5472.CAN-15-0361","volume":"76","author":"T Ishiguro","year":"2016","unstructured":"Ishiguro T, Sato A, Ohata H, Ikarashi Y, Takahashi R-U, Ochiya T et al. Establishment and characterization of an in vitro model of ovarian cancer stem-like cells with an enhanced proliferative capacity. Cancer Res 2016; 76: 150\u2013160.","journal-title":"Cancer Res"},{"key":"BFonc2017279_CR62","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1593\/neo.11138","volume":"13","author":"AA Jazaeri","year":"2011","unstructured":"Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011; 13: 899\u2013911.","journal-title":"Neoplasia"},{"key":"BFonc2017279_CR63","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1016\/j.tetlet.2014.10.122","volume":"55","author":"H Kothayer","year":"2014","unstructured":"Kothayer H, Morelli M, Brahemi G, Elshanawani AA, Abu Kull ME, El-Sabbagh OI et al. Optimised synthesis of diamino-triazinylmethyl benzoates as inhibitors of Rad6B ubiquitin conjugating enzyme. Tetrahedron Lett 2014; 55: 7015\u20137018.","journal-title":"Tetrahedron Lett"},{"key":"BFonc2017279_CR64","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.molcel.2011.01.024","volume":"41","author":"F Zhang","year":"2011","unstructured":"Zhang F, Yu X . WAC, a functional partner of RNF20\/40, regulates histone H2B ubiquitination and gene transcription. Mol Cell 2011; 41: 384\u2013397.","journal-title":"Mol Cell"},{"key":"BFonc2017279_CR65","doi-asserted-by":"publisher","first-page":"28816","DOI":"10.18632\/oncotarget.5006","volume":"6","author":"DW Clark","year":"2015","unstructured":"Clark DW, Tripathi K, Dorsman JC, Palle K . FANCJ protein is important for the stability of FANCD2\/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation. Oncotarget 2015; 6: 28816\u201328832.","journal-title":"Oncotarget"},{"key":"BFonc2017279_CR66","doi-asserted-by":"publisher","first-page":"31513","DOI":"10.1074\/jbc.M114.606483","volume":"289","author":"K Tripathi","year":"2014","unstructured":"Tripathi K, Mani C, Barnett R, Nalluri S, Bachaboina L, Rocconi RP et al. Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors. J Biol Chem 2014; 289: 31513\u201331525.","journal-title":"J Biol Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2017279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017279","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:06:15Z","timestamp":1647893175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":66,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017,11,30]]}},"alternative-id":["BFonc2017279"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.279","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"assertion":[{"value":"20 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}